Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million
42% of fourth quarter revenue from recurring patient sources
Record 241 authorizations and orders in the quarter
Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue
Conference call begins today at 4:30pm Eastern time
BURLINGTON, Mass. (March 9, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025.
“We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics (“O&P”) and International sales channels. We also achieved our strongest quarter of the year for MyoPro authorizations and orders,” said Paul Gudonis, Myomo’s Chairman and Chief Executive Officer. “We look forward to improved results from our 2026 marketing initiatives as we place greater emphasis on referrals and other recurring patient sources with a lower customer acquisition cost.” Read more.